Alnylam Pharmaceuticals Prices Upsized $575 Million Convertible Senior Notes Offering, Strengthening Balance Sheet and Advancing Growth Strategy Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a recognized global leader in RNA interference (RNAi) therapeutics, has announced the successful pricing of its private offering…
Cascade Bio Secures $6 Million to Advance Biocatalyst Innovation and Transform Biomanufacturing In a world grappling with climate change, supply chain disruptions, and the growing demand for sustainable manufacturing, biotechnology companies are racing to create alternatives to petrochemical-based production. Cascade…
JCR Pharmaceuticals Showcases Landmark Five-Year Clinical Data on Pabinafusp Alfa at ICIEM 2025, Reinforcing Transformative Potential for Patients with Hunter Syndrome and Expanding Pipeline of Brain-Penetrant Enzyme Replacement Therapies In early September 2025, the city of Kyoto, Japan, became the…
Roche’s Vabysmo Reinforces Long-Term Benefits in Wet Age-Related Macular Degeneration and Shows Strong Gains in Polypoidal Choroidal Vasculopathy Paris, France – At the 25th annual Euretina Congress, one of the world’s most important scientific gatherings focused on retinal disease, Roche…
Octave Bioscience Secures $35.6 Million Series C Financing and $15.5 Million Loan to Accelerate Growth and Advance Precision Care in Neurology Octave Bioscience, Inc., a commercial-stage precision care company dedicated to transforming the management of neurodegenerative diseases, has announced a…
Walgreens Embarks on New Era as Private Standalone Company Following Acquisition by Sycamore Partners Walgreen Co. (“Walgreens” or “the Company”), one of America’s most iconic retail pharmacy chains and a cornerstone of healthcare access for millions of Americans, announced today…
Evolus Reports Positive Pivotal Trial Data for Evolysse™ Sculpt Hyaluronic Acid Gel at 2025 Cosmetic Bootcamp, Marking a Major Milestone in Aesthetic Innovation Evolus, Inc. (NASDAQ: EOLS), a fast-growing performance beauty company dedicated to reshaping the aesthetic medicine landscape, announced…
Sarepta Therapeutics Restructures $700 Million in Convertible Debt, Extending Maturities and Strengthening Financial Flexibility Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leader in precision genetic medicine focused on rare diseases, has announced a significant refinancing transaction designed to strengthen its capital…
Sensory Cloud Reports Encouraging Phase 2a REACH Trial Results for Novel Aerosol Therapy in Refractory Chronic Cough Sensory Cloud Inc., a clinical-stage biopharmaceutical company developing first-in-class therapies targeting mechano-sensitive ion channels in the respiratory system, together with collaborators at King…
PharmaCyte Biotech Strengthens Financial Position with $7 Million Private Placement Led by Existing Investors Financing provides strategic capital infusion to support corporate initiatives, enhance balance sheet, and advance long-term value creation plans PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the…
IntegriChain Appoints New Chief AI and Technology Officer to Lead Next Era of Innovation, Automation, and Customer Experience in Life Sciences IntegriChain, a recognized market leader in net revenue optimization technology and commercial data insights for the life sciences industry,…
TriSalus Life Sciences Announces Strong Q2 2025 Results, Affirms Full-Year Outlook, and Advances Strategic Focus on Liver-Directed Therapies TriSalus Life Sciences, Inc. (Nasdaq: TLSI), an oncology company pioneering innovative delivery solutions for treating solid tumors, today reported its financial results…
